A Better Path to Well

Bringing the science of precision to Therapeutics

Vector Science & Therapeutics develops novel biomechanical devices and active localized drug delivery platforms to equip clinicians with site-directed interventions where precision matters and systemic risk are unacceptable.

Our Mission Get In Touch
TSXV PAIN
- CAD
Open- High- Low- Vol-
Pending Listing
Investor Relations →
TSXV
Exchange Listing
Symbol: PAIN
TSX Venture Exchange
Our Approach

Smart. Steered. Sustained.

Three pillars. One platform. From adaptive intelligence to site-directed delivery to continuous therapeutic presence - without systemic side effects.

Smart

Intelligent, data-informed formulations and devices that respond to tissue conditions - delivering exactly what the body needs, when it needs it.

Steered

Precisely directed therapies using active transdermal platforms that guide therapeutic compounds to exactly the right anatomical target site.

Sustained

Long-lasting therapeutic effects that support true musculoskeletal tissue regeneration - moving beyond symptom masking to genuine, durable healing.

Smart, Steered, Sustained - one integrated platform narrative A left-to-right story: adaptive intelligence informs a steered delivery to a target site, which sustains a therapeutic effect across time. TOXIC SUB-THERAPEUTIC ADAPTIVE SENSING SURFACE BARRIER INTERMEDIATE TISSUE DEEP TISSUE TARGET SITE-DIRECTED DELIVERY TOXIC SUB-THERAPEUTIC START TIME DURATION VECTOR - STEADY CONVENTIONAL CONTINUOUS PRESENCE
I · Intelligence Smart
II · Delivery Steered
III · Duration Sustained

One throughline. Right therapy, right place, right duration.

Press & Updates

Latest News

All News
July 24, 2026 Press Release

Vector Science & Therapeutics Reports First Quarterly Financial Results as a Public Company; Announces Inaugural Investor Q&A on July 28

Vector Science & Therapeutics Corp. (TSXV: PAIN) today announced the filing of its first quarterly financial statements and Management’s Discussion & Analysis since completing its going-public reverse takeover with OpenSesame Acquisition Corp. on April 23, 2026, and announced its inaugural quarterly investor Q&A, held via Microsoft Teams on July 28, 2026.

Continue Reading
July 21, 2026 Press Release

Vector Science & Therapeutics Announces Distributor Network Buildout to Support Its Peptide Portfolio Across Orthopedic, Sports, and Regenerative Medicine Channels

Vector Science & Therapeutics Corp. (TSXV: PAIN) today announced plans to build a dedicated distributor network to support commercialization of its peptide portfolio across the orthopedic, sports, and regenerative medicine channels, focused on musculoskeletal conditions, soft tissue injury, and degenerative joint disease, including osteoarthritis.

Continue Reading
July 17, 2026 Press Release

Vector Science & Therapeutics and Caresyntax Announce Real-World Evidence Partnership for VectorMist

Vector Science & Therapeutics Corp. (TSXV: PAIN) and Caresyntax, a global leader in surgical intelligence and real-world evidence, today announced a strategic partnership to build the clinical evidence infrastructure supporting VectorMist™, Vector’s localized atomized drug delivery platform, and The LASSO Protocol™ (Laparoscopic Atomization System for Sparing Opioids).

Continue Reading
Work With Us

We welcome conversations with investors, clinical partners, and healthcare organizations aligned with our mission.

Get In Touch info@vectorscience.co